Patent classifications
C12N2770/36034
Zika RNA vaccines
Aspects of the disclosure describe compositions that comprise RNA polynucleotides having an open reading frame encoding one or more Zika virus antigens. Methods for preparing and using the compositions are also described.
Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.
DNA Antibody Constructs And Method Of Using Same
Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating disease in a subject using said composition and method of generation.
INFECTIOUS DISEASE VACCINES
Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.
DNA ANTIBODY CONSTRUCTS AND METHOD OF USING SAME
Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating disease in a subject using said composition and method of generation.
DENV RNA VACCINES
Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.
CHIKV RNA VACCINES
Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.
ZIKA RNA VACCINES
Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.
GENERATION OF ANTIBODIES TO TUMOR ANTIGENS AND GENERATION OF TUMOR SPECIFIC COMPLEMENT DEPENDENT CYTOTOXICITY BY ADMINISTRATION OF ONCOLYTIC VACCINIA VIRUS
The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.
EXOSOMES AND THEIR USE AS VACCINE
The present invention provides exosomes isolated from an animal, wherein the animal (a) has overcome a disease caused by a pathogen, and (b) it is free from the pathogen that causes the diseases. The invention also provides process for obtaining these exosomes and the use thereof in therapy.